Public neoantigens in breast cancer immunotherapy (Review)
Issued Date
2024-07-01
Resource Type
ISSN
11073756
eISSN
1791244X
Scopus ID
2-s2.0-85196409258
Journal Title
International Journal of Molecular Medicine
Volume
54
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Molecular Medicine Vol.54 No.1 (2024)
Suggested Citation
Sueangoen N., Thuwajit P., Yenchitsomanus P.T., Thuwajit C. Public neoantigens in breast cancer immunotherapy (Review). International Journal of Molecular Medicine Vol.54 No.1 (2024). doi:10.3892/ijmm.2024.5388 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99015
Title
Public neoantigens in breast cancer immunotherapy (Review)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Among women globally, breast cancer is the most prevalent cancer and the leading cause of cancer‑related death. Interestingly, though genetic mutations contribute to the disease, <15% of women diagnosed with breast cancer have a family history of the disease, suggesting a prevalence of sporadic genetic mutations in breast cancer development. In the rapidly rising field of cancer genomics, neoantigen‑based immunotherapy has come to the fore. The investigation of novel proteins arising from unique somatic mutations or neoantigens have opened a new pathway for both individualized and public cancer treatments. Because they are shared among individuals with similar genetic changes, public neoantigens provide an opportunity for ‘off‑the‑shelf’ anticancer therapies, potentially extending the benefits to a wider patient group. The present review aimed to highlight the role of shared or public neoan‑ tigens as therapeutic targets for patients with breast cancer, emphasizing common hotspot mutations of certain genes identified in breast cancer. The clinical utilization of public neoantigen‑based therapies for breast cancer treatment were also discussed.